医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MC10, Inc. Partners with Marubun Corporation to add Japanese Distribution Network

2016年04月06日 PM10:00
このエントリーをはてなブックマークに追加


 

LEXINGTON, Mass. & TOKYO

MC10, Inc., the healthcare technology company specializing in stretchable body worn computing systems, and Marubun Corporation, the leading Japanese distributor of cutting-edge technology products, have entered into a limited exclusive distribution relationship for MC10’s line of BioStamp® products. The BioStamp conformal sensing platform enables previously rigid technology to move and bend with the human body while collecting valuable biometric data.

This partnership will enhance MC10’s international presence, allowing Marubun to introduce MC10’s groundbreaking BioStamp Research Connect™ System (BioStampRC™) to its large partner network in Japan.

“Marubun strives to contribute to the advancement of science and technology by engaging with suppliers who are leaders in their respective fields and providing cutting-edge specialized electronics,” said Satoshi Fujino, Marubun’s Senior Vice President. “Through our relationship with MC10, we are continuing in our mission to deliver the most innovative technology to our customers.”

The recently unveiled BioStampRC System provides a complete solution for researchers to seamlessly gather and manage physiological data. The end-to-end system consists of MC10’s proprietary soft stretchable sensors as well as cloud based storage and analytical tools, enabling innovators to easily design physiological monitoring studies and collect and share biometric data with collaborators.

“MC10 is dedicated to developing technology that enables a better understanding of human health. My past engagements with Marubun have demonstrated the corporation’s superior ability to bring new, emerging technologies to the Japanese market,” commented Scott Pomerantz, President and Chief Executive Officer of MC10.

In addition to the distribution partnership, Marubun has also joined a strong syndicate of strategic equity investors committed to growing MC10’s product presence globally.

About MC10, Inc.

MC10 is a private company, backed by a strong syndicate of financial and strategic investors, that is improving human health through digital healthcare solutions. The company combines its proprietary ultra-thin, flexible body-worn sensors with advanced analytics to unlock health insights from physiological data. MC10 has received widespread recognition for its revolutionary technology and was recently named in Fast Company’s Most Innovative Companies in 2016 as a leader in healthcare. MC10 is headquartered in Lexington, MA. Visit MC10 online at www.mc10inc.com.

BioStamp Research Connect™, BioStampRC™, BioStamp®, MC10® and the MC10 logo are registered marks owned by MC10, Inc.

About Marubun
MARUBUN CORPORATION, listed on 1st section of Tokyo Stock Exchange, is a trading company engaged in the purchase and sale of semiconductors, general electronic components, and electronic products. Marubun supplies cutting-edge electronics products that play pivotal roles in numerous fields, which include automobile telecommunication industrial equipment and Medical Equipment.

We understand our customers’ needs, and in order to provide products that meet those needs, create systems, combine them with other products, and use information networks to find products, so that we can satisfy customer needs in the shortest possible time. Only a technology-oriented trading company such as Marubun can carry out these types of detailed activities. For more information, please visit http://www.marubun.co.jp/en/aboutus/index.html.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160406005293/en/

CONTACT

For MC10
Erin Webster, 857-214-5663
Press@mc10inc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Mitsui Chemicals Develops AIRYFA™The World’s First Flexible Nonwoven with High Strength
  • Quidel Receives PMDA Approval for Its Point-of-Care Sofia® Influenza A+B Assay
  • ドンペが中等度および重度の成人神経栄養性角膜炎患者の治療薬としてのOxervate®(Cenegermin点眼薬)に対するCHMPの肯定的意見を欧州で受領
  • Takeda Showcases Broadened Oncology Portfolio Through Data Presentations at Upcoming Medical Meetings
  • GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in Japan